Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
amcinonide
Overview
What is amcinonide?
The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.
Each gram of Amcinonide Lotion, 0.1% contains 1 mg of the active steroid amcinonide in a white, smooth, homogeneous, opaque emulsion composed of Benzyl Alcohol 1% (wt/wt) as preservative, Emulsifying Wax, Glycerin, Isopropyl Palmitate, Purified Water, Sorbitol Solution and Polyethylene Glycol 400. Dilute Lactic Acid is used for pH adjustment, if required. Chemically, amcinonide is:
Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-16,17-[cyclopentylidenebis(oxy)]-9-fluoro-11-hydroxy-, (11β, 16α).
What does amcinonide look like?
What are the available doses of amcinonide?
Sorry No records found.
What should I talk to my health care provider before I take amcinonide?
Sorry No records found
How should I use amcinonide?
Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Topical corticosteroids are generally applied to the affected area as a thin film from two to three times daily depending on the severity of the condition.
The lotion may be applied topically to the specified lesions, particularly to those in hairy areas, two times per day. The lotion should be rubbed into the affected area completely, and the area should be protected from washing, clothing, rubbing, etc. until the lotion is dried.
Occlusive dressings may be a valuable therapeutic adjunct for the management of psoriasis or recalcitrant conditions.
If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
What interacts with amcinonide?
Sorry No Records found
What are the warnings of amcinonide?
Sorry No Records found
What are the precautions of amcinonide?
Sorry No Records found
What are the side effects of amcinonide?
In the clinical trials with Amcinonide Lotion, the investigators reported a 4.7% incidence of side effects. In a weekly acceptability evaluation, approximately 20% of the patients treated with Amcinonide Lotion or placebo reported itching, stinging, soreness, or burning at one or more of the visits.The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.
What should I look out for while using amcinonide?
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
What might happen if I take too much amcinonide?
Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see ).
How should I store and handle amcinonide?
Store in a dry place protected from light.Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Store in a dry place protected from light.Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Amcinonide Lotion, 0.1% is supplied as follows: NDC 0168-0280-60 60 mL bottle Store at controlled room temperature 15° to 30°C (59° to 86°F) DO NOT FREEZE. E. FOUGERA & CO.FougeraI2280CR07/12#84 Amcinonide Lotion, 0.1% is supplied as follows: NDC 0168-0280-60 60 mL bottle Store at controlled room temperature 15° to 30°C (59° to 86°F) DO NOT FREEZE. E. FOUGERA & CO.FougeraI2280CR07/12#84 Amcinonide Lotion, 0.1% is supplied as follows: NDC 0168-0280-60 60 mL bottle Store at controlled room temperature 15° to 30°C (59° to 86°F) DO NOT FREEZE. E. FOUGERA & CO.FougeraI2280CR07/12#84 Amcinonide Lotion, 0.1% is supplied as follows: NDC 0168-0280-60 60 mL bottle Store at controlled room temperature 15° to 30°C (59° to 86°F) DO NOT FREEZE. E. FOUGERA & CO.FougeraI2280CR07/12#84 Amcinonide Lotion, 0.1% is supplied as follows: NDC 0168-0280-60 60 mL bottle Store at controlled room temperature 15° to 30°C (59° to 86°F) DO NOT FREEZE. E. FOUGERA & CO.FougeraI2280CR07/12#84 Amcinonide Lotion, 0.1% is supplied as follows: NDC 0168-0280-60 60 mL bottle Store at controlled room temperature 15° to 30°C (59° to 86°F) DO NOT FREEZE. E. FOUGERA & CO.FougeraI2280CR07/12#84 Amcinonide Lotion, 0.1% is supplied as follows: NDC 0168-0280-60 60 mL bottle Store at controlled room temperature 15° to 30°C (59° to 86°F) DO NOT FREEZE. E. FOUGERA & CO.FougeraI2280CR07/12#84
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions.
The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.
Non-Clinical Toxicology
Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.As with other drugs, the potential for interaction by a variety of mechanisms (e.g., pharmacodynamic, pharmacokinetic inhibition or enhancement, etc.) is a possibility (see ).
General:
Conditions that augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA-axis suppression by using the urinary free-cortisol and ACTH stimulation tests. If HPA-axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute with a less potent steroid.
Recovery of HPA-axis function is generally prompt and complete upon discontinuation of the drug.
Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.
Pediatric patients may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see ).
If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted.
In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.
The products are not for ophthalmic use.
In the clinical trials with Amcinonide Lotion, the investigators reported a 4.7% incidence of side effects. In a weekly acceptability evaluation, approximately 20% of the patients treated with Amcinonide Lotion or placebo reported itching, stinging, soreness, or burning at one or more of the visits.The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).